Dianthus Therapeutics, Inc. DNTH 深 沪
交易中 07-13 11:06:22 美东时间
96.785
-0.815
-0.84%
华盛通- 最 高97.24
- 今 开96.33
- 成交量 9.49万股
- 最 低 93.85
- 昨 收 97.60
- 总市值 52.91亿
- 52周最高 102.33
- 市盈率 静 --
- 换手率 0.17%
- 52周最低 18.08
- 委 比 -64.80%
- 总股本 5466.62万
- 历史最高 336.00
- 量 比 0.40
- 振 幅 3.47%
- 历史最低 5.136
- 每 手 1
- 风险率 25.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Is Dianthus Therapeutics Stock Trading Higher On Friday?
Dianthus Therapeutics Inc. (NASDAQ:DNTH) reported stronger-than-expected midstage results from its CAPTIVATE Phase 3 trial of claseprubart (DNTH103) in chronic inflammatory demyelinating polyneuropathy (CIDP). An interim analysis of 40 patients completing Part A showed a 75% confirmed responder rate...
06-13 01:20
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position: Analyst
Sanofi SA (NASDAQ:SNY) on Wednesday announced that it will discontinue its Phase 3 MOBILIZE study evaluating riliprubart in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who had not responded to standard treatments. CIDP is a rare, acquired autoimmune disorder of the periphe...
06-11 21:09
今日药闻 | BI、GSK、拜耳、礼来等新进展……
1.5月6日，瑞博生物宣布与勃林格殷格翰（BI）在代谢功能障碍相关脂肪性肝炎（MASH）领域的siRNA合作达成第三个关键里程碑 此次进展标志着双方合作研发进...
05-07 17:24
美股大行评级 | 潜在涨幅20%！15家机构集体上调AMD目标价；Lumentum、神经分泌生物科学、伊顿公司、美国电力等获多家大行上调目标价
今日重点评级关注：Citizens：维持Avalo Therapeutics"跑赢大市"评级，目标价从52美元升至62美元；BTIG：维持Avalo Therapeutics"买入"评级，目标价从40美元升至58美元
05-07 12:37
Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $105
Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $103 to $105.
05-06 20:45
Dianthus Therapeutics Q1 EPS $(0.85) Beats $(1.07) Estimate, Sales $463.000K Beat $354.214K Estimate
Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(0.85) per share which beat the analyst consensus estimate of $(1.07) by 20.56 percent. This is a 3.66 percent decrease over losses of $(0.82) per share
05-06 04:29
美股大行评级 | 小摩上调Lumentum控股目标价从565美元升至950美元；大小摩齐上调美国铝业目标价
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从13美元升至13.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8.25美元升至9美元
04-10 18:27
Wolfe Research Initiates Coverage On Dianthus Therapeutics with Outperform Rating, Announces Price Target of $98
Wolfe Research analyst Andy Chen initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform rating and announces Price Target of $98.
04-10 00:34
美股大行评级 | 最高700美元！大摩、瑞银等10家大行集体上调美光目标价；通用磨坊、梅西百货、SailPoint等遭多家大行下调目标价
今日重点评级关注：RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从32美元升至35美元；巴克莱：维持CytomX医疗"超配"评级，目标价从10美元升至16美元
03-20 15:53
This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Wall Street analysts changed outlook on top names. Clear Street initiated coverage on RKLB with Buy rating, $88 PT. See analyst ratings.
03-19 21:14
